novavax fda news - Search News

Novavax Gets FDA Approval To Resume Testing 2 Vaccines

Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold

The company explained that the U.S. Food and Drug Administration (FDA) removed its clinical hold on the studies, and will allow it "to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical ...

KSL · 2d

FDA lifts clinical hold on Novavax's combo COVID-flu shot

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after identifying a safety concern.

biopharma-reporter · 2d

FDA removes clinical hold on Novavax’s COVID-19-influenza combo vaccine

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.

Novavax sees weak Covid vaccine sales

Reuters · 1d

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales

The company is banking on revenue from its Sanofi deal and vaccines in development, including an experimental COVID-flu combination shot, which Novavax said this week got the green light from the U.S. FDA to resume clinical testing. Novavax does not expect ...

The Business Journals · 1d

Novavax sees weak Covid vaccine sales, convinced Sanofi can do better

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.

Seeking Alpha on MSN · 2d

Novavax falls after guidance cut on lower vaccine sales

Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 financials, cut its full-year revenue guidance, citing a gloomy sales outlook for its COVID-19 vaccine,

Becker's Hospital Review1d

FDA lifts clinical hold on combined COVID-19-influenza vaccine trials

Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC) and standalone influenza vaccines. The FDA lifted a clinical ...

Novavax Gains Competitive Edge with FDA Clearance and Strategic Collaborations, Earning Buy Rating

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax (NVAX – Research Report) today and set a price target of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novavax Gets FDA Approval To Resume Testing 2 Vaccines

Novavax sees weak Covid vaccine sales

Trending now